14 de octubre de 2019
  • Domingo, 13 de Octubre
  • Sábado, 12 de Octubre
  • 15 de mayo de 2009

    Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 (1)

    For Non-US Journalists Only
    Boehringer Ingelheim Oncology: A podcast update from ASCO 2009
    Available from Saturday 16th May 2009

    Visit http://www.personalisingcancercare.com to find out more about
    Boehringer Ingelheim's compounds and watch experts Dr. James Spicer and
    Dr. Rolf Kaiser discuss the significance of these exciting trial results.

    Notes to editors

    About Lung Cancer

    Lung cancer is the world's most common cancer and kills more people than any other cancer. (3,14) In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).(15)

    About Ovarian Cancer

    According to the 2008 World Health Organization World Cancer Report, as of 2002, ovarian cancer was ranked as the 6th most common cancer in women. Additionally, approximately 204,000 new cases were diagnosed worldwide and 125,000 women died from the disease in 2002.(14) The ACS estimates that about 21,650 new cases of ovarian cancer were diagnosed in the United States (U.S.) during 2008. Only forty-five percent of women with ovarian cancer are still alive at least five years after diagnosis in the U.S.(16)

    About Boehringer Ingelheim in Oncology